COSMOS Pharmaceutical Corporation (TYO:3349)
Japan · Delayed Price · Currency is JPY 9,543.00
+113.00 (1.20%)
Aug 1, 2025, 3:30 PM JST
Exscientia Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 | 2016 - 2020 |
| 1,011,390 | 964,989 | 827,697 | 755,414 | 726,424 | Upgrade | |
Revenue Growth (YoY) | 4.81% | 16.59% | 9.57% | 3.99% | 6.14% | Upgrade |
Cost of Revenue | 798,109 | 776,683 | 658,979 | 603,966 | 581,313 | Upgrade |
Gross Profit | 213,281 | 188,306 | 168,718 | 151,448 | 145,111 | Upgrade |
Selling, General & Admin | 173,341 | 138,536 | 122,807 | 107,756 | 99,163 | Upgrade |
Operating Expenses | 173,341 | 156,804 | 138,589 | 121,651 | 111,964 | Upgrade |
Operating Income | 39,940 | 31,502 | 30,129 | 29,797 | 33,147 | Upgrade |
Interest Expense | -254 | -99 | -51 | -52 | -60 | Upgrade |
Interest & Investment Income | 48 | 44 | 47 | 52 | 57 | Upgrade |
Other Non Operating Income (Expenses) | 2,921 | 2,852 | 2,960 | 3,063 | 2,690 | Upgrade |
EBT Excluding Unusual Items | 42,655 | 34,299 | 33,085 | 32,860 | 35,834 | Upgrade |
Merger & Restructuring Charges | -64 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 503 | 75 | - | 265 | 4,190 | Upgrade |
Asset Writedown | -508 | -1,010 | -113 | -70 | -31 | Upgrade |
Other Unusual Items | -222 | 355 | -200 | -8 | -1,398 | Upgrade |
Pretax Income | 42,372 | 33,719 | 32,772 | 33,047 | 38,595 | Upgrade |
Income Tax Expense | 11,394 | 9,265 | 8,975 | 9,892 | 11,439 | Upgrade |
Net Income | 30,978 | 24,454 | 23,797 | 23,155 | 27,156 | Upgrade |
Net Income to Common | 30,978 | 24,454 | 23,797 | 23,155 | 27,156 | Upgrade |
Net Income Growth | 26.68% | 2.76% | 2.77% | -14.73% | 26.69% | Upgrade |
Shares Outstanding (Basic) | 79 | 79 | 79 | 79 | 79 | Upgrade |
Shares Outstanding (Diluted) | 79 | 79 | 79 | 79 | 79 | Upgrade |
Shares Change (YoY) | 0.02% | 0.05% | - | - | - | Upgrade |
EPS (Basic) | 390.85 | 308.61 | 300.48 | 292.37 | 342.89 | Upgrade |
EPS (Diluted) | 390.85 | 308.61 | 300.48 | 292.37 | 342.89 | Upgrade |
EPS Growth | 26.65% | 2.71% | 2.77% | -14.73% | 26.69% | Upgrade |
Free Cash Flow | -859 | -635 | 7,798 | -11,303 | 1,811 | Upgrade |
Free Cash Flow Per Share | -10.84 | -8.01 | 98.46 | -142.72 | 22.87 | Upgrade |
Dividend Per Share | 70.000 | 60.000 | 50.000 | 40.000 | 35.000 | Upgrade |
Dividend Growth | 16.67% | 20.00% | 25.00% | 14.29% | 27.27% | Upgrade |
Gross Margin | 21.09% | 19.51% | 20.38% | 20.05% | 19.98% | Upgrade |
Operating Margin | 3.95% | 3.26% | 3.64% | 3.94% | 4.56% | Upgrade |
Profit Margin | 3.06% | 2.53% | 2.88% | 3.06% | 3.74% | Upgrade |
Free Cash Flow Margin | -0.08% | -0.07% | 0.94% | -1.50% | 0.25% | Upgrade |
EBITDA | 62,169 | 51,426 | 47,497 | 44,907 | 46,932 | Upgrade |
EBITDA Margin | 6.15% | 5.33% | 5.74% | 5.95% | 6.46% | Upgrade |
D&A For EBITDA | 22,229 | 19,924 | 17,368 | 15,110 | 13,785 | Upgrade |
EBIT | 39,940 | 31,502 | 30,129 | 29,797 | 33,147 | Upgrade |
EBIT Margin | 3.95% | 3.26% | 3.64% | 3.94% | 4.56% | Upgrade |
Effective Tax Rate | 26.89% | 27.48% | 27.39% | 29.93% | 29.64% | Upgrade |
Advertising Expenses | - | 1,812 | 1,648 | 1,632 | 2,784 | Upgrade |
Updated Jan 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.